KEAP1-NFE2L2突变在NSCLC中的临床意义
KEAP1-NFE2L2通路突变在非小细胞肺癌(NSCLC)中常见,与肿瘤生长和侵袭性增强相关,且临床前和临床研究报道该通路突变导致对放疗、化疗和靶向治疗难治。免疫治疗在该人群中的疗效尚不明确,研究结论存在冲突。本文综述了KEAP1-NFE2L2突变肿瘤中几类抗癌治疗的现有临床证据,并概述了当前临床试验格局,重点提及mTORC1、mTORC2和谷氨酰胺酶抑制的研究。
要点
- KEAP1-NFE2L2通路突变在NSCLC中常见,与肿瘤生长和侵袭性增强相关。
- 该通路突变与放疗、化疗和靶向治疗难治相关。
- 免疫检查点抑制剂在该突变人群中的疗效研究结论存在冲突。
核心结论
- KEAP1-NFE2L2通路突变NSCLC对放疗、化疗和靶向治疗难治,免疫治疗疗效尚不明确且研究结论冲突。
研究设计与样本
- 综述,总结KEAP1-NFE2L2突变肿瘤中几类抗癌治疗的当前临床证据,并概述当前临床试验格局。
主要发现
- 临床前和临床研究报道KEAP1-NFE2L2通路突变肿瘤对放疗、化疗和靶向治疗难治。
- 免疫检查点抑制剂在KEAP1-NFE2L2突变NSCLC中的疗效研究结论存在冲突。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The KEAP1-NFE2L2 pathway is an important modulator of cell homeostasis. Mutations in this pathway are common in NSCLC and have been associated with enhanced tumor growth and aggressiveness. In addition, tumors with mutations in the KEAP1-NFE2L2 pathway have been reported in preclinical and clinical studies to convey refractoriness to cancer-directed therapy such as radiation, chemotherapy, and targeted therapy. The role of immunotherapy in this patient population is less clear, and there are conflicting studies on the efficacy of immune checkpoint inhibitors in KEAP1-NFE2L2-mutant NSCLC. Here, we review the current clinical evidence on several classes of anticancer therapeutics in KEAP1-NFE2L2-mutant tumors. Furthermore, we provide an overview of the landscape of the current clinical trials in this patient population, highlighting the work being done with mTORC1, mTORC2, and glutaminase inhibition.
引用
- Hellyer JA, Padda SK, Diehn M, et al. Clinical Implications of KEAP1-NFE2L2 Mutations in NSCLC. J Thorac Oncol. 2020. PMID: 33307193. doi:10.1016/j.jtho.2020.11.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。